Preventing Postpartum Depression With Intranasal Oxytocin
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new treatment for preventing childbirth-related mental
illness in postpartum mothers. The treatment is aimed at enhancing maternal bonding, reducing
postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development.
To this end, the investigators will test the clinical utility of intranasal (IN) oxytocin
(OXT) administered to mothers during the first postpartum days.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)